Abstracts

Dynamics of the Intact HIV Reservoir During ART Following Analytical Treatment Interruption

Background: To assess efficacy, clinical trials evaluating therapeutic agents aimed at achieving HIV cure or sustained virologic remission require analytical treatment interruption (ATI). It has been shown that ATI results in the expansion of HIV reservoirs in people living with HIV (PLWH) with rebounding plasma viremia; however, the dynamics of the intact HIV reservoir during…

Immune Responses and HIV Reservoir Evolution From Pre-ART to 5 Years Into Post-Treatment Control

Background: In the randomized-controlled eCLEAR study focusing on the administration of the broadly neutralizing antibody 3BNC117 at the time of ART initiation, one post-treatment controller was identified. He initiated ART and 3BNC117 during primary HIV-1 infection (plasma viral load of 188,945 copies/mL and CD4 counts of 470 cells/mm3) and has had sustained virologic control for…

CD101 Variants Are Associated With Lower Levels of Genital HIV-Inhibiting and Tissue Repair Factors

Background: We previously demonstrated that Africans with variants in the Ig-like domain of CD101 are associated with an increased risk of heterosexually acquired HIV infection. Recognizing that CD101 has known immunoregulatory functions, we had shown that these CD101 Ig-like variants are associated with reduced regulatory T cell function and increased proinflammatory T cell responses in…

The Fraction of HIV Reservoir Variants Neutralized by Autologous IgG Correlates With Time to Rebound

Background: During untreated infection, HIV-1 rapidly evolves to escape contemporaneous, autologous neutralizing antibodies (anAbs). At the time of ART initiation, archived reservoir isolates may be sensitive or resistant to anAbs. Factors such as time to rebound, and the genotype of rebound virus are difficult to predict amongst analytical treatment interruption (ATI) cohorts. Elucidating the factors…

Immunosuppressive Effects of LLDT-8 in ART-Treated SIV-Infected Rhesus Macaques

Background: Chronic immune activation plays a significant role in the pathogenesis and disease progression of human immunodeficiency virus (HIV), and the existing interventions to address this issue are limited. In a phase II clinical trial, (5R)-5-hydroxytriptolide (LLDT-8) demonstrated promising potential in enhancing CD4+ T cell recovery. However, the precise mechanism of action of LLDT-8 remains…